IJT - CIR - February 2024 - 62S

62S
International Journal of Toxicology 43(Supplement 1)
Triphosphate1 are safe in cosmetics in the present practices of
use and concentrations described in the safety assessment.
Author Contributions
The articles in this supplement were sponsored by the Cosmetic
Ingredient Review.
Author's Note
Unpublished sources cited in this report are available from the Director,
Cosmetic Ingredient Review, 1620L Street, NW, Suite 1200,
Washington, DC 20036, USA.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: The articles in this supplement were sponsored by the
Cosmetic Ingredient Review.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication ofthis article: The articles
in this supplement were sponsored by the Cosmetic Ingredient Review.
The Cosmetic Ingredient Review is financially supported by the
Personal Care Products Council.
Note
1. Not reported to be in current use. Were this ingredient not in
current use to be used in the future, the expectation is that it would
be used in product categories and at concentrations comparable to
others in this group.
References
1. Nikitakis J, Kowcz A. wINCI: International Cosmetic Ingredient
Dictionary and Handbook. Washington, DC: Personal
Care Products Council; 2020. Last Updated. https://
webdictionary.personalcarecouncil.org/jsp/Home.jsp. Accessed
August 20, 2020.
2. European Chemicals Agency (ECHA). Adenosine. https://echa.
europa.eu/registration-dossier/-/registered-dossier/23062. Last
Updated: 2019. Accessed May 17, 2019.
3. U.S. National Institute of Health (NIH). National Cancer Institute
(NCI). NCIthesaurus: adenosine triphosphate (Code
C209). https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?
dictionary=NCI_Thesaurus&ns=ncit&code=C209. Last Updated:
2019. Accessed: May 29, 2019.
4. Bonora M, Patergnani S, Rimessi A, et al. ATP Synthesis and
storage. Purinergic Signal. 2012;8(3):343-357.
5. Sheth S, Brito R, Mukherjea D, Rybak L, Ramkumar V.
Adenosine receptors: expression, function, and regulation. Int J
Mol Sci. 2014;15:2024-2052.
6. Zhang C, Du S, Guo L, Xu Q, Xie X, Chen N. Enhancement of
adenosine production by over expression of purA in Bacillis
subtilis XGL. J Chem Pharmaceut Res. 2014;6(6):549-555.
7. Yun J, Shen S, Chen F, Yao K. One-step isolation of adenosine
triphosphate from crude fermentation broth of Saccharomyces
cerevisiae by anion exchange chromatography using supermacroporous
cryogel. J Chromatogr, B: Anal Technol Biomed
Life Sci. 2007;860(1):57-62.
8. Anonymous. Adenosine specifications. 2019. (Unpublished
data submitted by the Personal Care Products Council on October
8, 2019).
9. Anonymous. Adenosine triphosphate: impurities. 2019. (Unpublished
data submitted by Personal Care Products Council on
November 19, 2019).
10. Anonymous. Disodium adenosine triphosphate. 2019. (Unpublished
data submitted by Personal Care Products Council on
October 15, 2019).
11. U.S. Food and Drug Administration Center for Food Safety and
Applied Nutrition (CFSAN). Voluntary Cosmetic Registration
Program - Frequency of use of cosmetic ingredients. College
Park, MD. 2020. (Obtained under the Freedom of Information
Act from CFSAN; requested as " Frequency of Use Data "
January 6, 2020; received January 13, 2020).
12. Personal Care Products Council. Concentration of use by FDA
product category: adenosine ingredients. 2018. (Unpublished
data submitted by Personal Care Products Council on May 31,
2018)
13. Johnsen M. The influence of particle size. Spray Technol Mark.
2004;14(11):24-27.
14. Rothe H. Special Aspects of Cosmetic Spray Evaluation.
Washington, DC: Expert Panel Meeting; 2011. Unpublished
data presented at the 26 September 2011.
15. Bremmer H, van Engelen JGM, LCH Prud'homme de
Lodder. Cosmetics fact sheet: to assess the risks for the
consumer. 2006:1. Updated version for ConsExpo4. https://
www.rivm.nl/bibliotheek/rapporten/320104001.pdf.Accessed
May 14, 19.
16. Rothe H, Fautz R, Gerber E, et al. Special aspects of cosmetic
spray safety evaluations: principles on inhalation risk assessment.
Toxicol Lett. 2011;205(2):97-104.
17. CIR Science and Support Committee of the Personal Care
Products Council (CIR SCC). (Nov 3rd) Cosmetic Powder
Exposure. The Personal Care Products Council; 2015. Unpublished
data submitted by.
18. Aylott R, Byrne G, Middleton J, Roberts M. Normal use levels
of respirable cosmetic talc: preliminary study. Int JCosmet Sci.
1979;1(3):177-186.
19. Russell R, Merz R, Sherman W, Sivertson JN. The determination
of respirable particles in talcum powder. Food Chem
Toxicol. 1979;17(2):117-122.
20. European Commission. European union inventory of cosmetic
ingredients. 2019. Last Updated. https://ec.europa.eu/growth/
tools-databases/cosing/index.cfm?fuseaction=search.simple.
Accessed July 29, 2019.
21. U.S. Food and Drug Administration (FDA). FDAwarns ofrare but
serious risk or heart attack and death with cardiac Nuclear stress test
drugs Lexiscan (regadenoson) and Adenoscan (adenosine). 2013.
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns
https://www.rivm.nl/bibliotheek/rapporten/320104001.pdf https://www.rivm.nl/bibliotheek/rapporten/320104001.pdf https://webdictionary.personalcarecouncil.org/jsp/Home.jsp https://webdictionary.personalcarecouncil.org/jsp/Home.jsp https://echa.europa.eu/registration-dossier/-/registered-dossier/23062 https://echa.europa.eu/registration-dossier/-/registered-dossier/23062 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C209 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C209 https://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.simple https://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.simple https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-test-drugs-lexiscan

IJT - CIR - February 2024

Table of Contents for the Digital Edition of IJT - CIR - February 2024

Contents
IJT - CIR - February 2024 - Cover1
IJT - CIR - February 2024 - Cover2
IJT - CIR - February 2024 - 1S
IJT - CIR - February 2024 - 2S
IJT - CIR - February 2024 - Contents
IJT - CIR - February 2024 - 4S
IJT - CIR - February 2024 - 5S
IJT - CIR - February 2024 - 6S
IJT - CIR - February 2024 - 7S
IJT - CIR - February 2024 - 8S
IJT - CIR - February 2024 - 9S
IJT - CIR - February 2024 - 10S
IJT - CIR - February 2024 - 11S
IJT - CIR - February 2024 - 12S
IJT - CIR - February 2024 - 13S
IJT - CIR - February 2024 - 14S
IJT - CIR - February 2024 - 15S
IJT - CIR - February 2024 - 16S
IJT - CIR - February 2024 - 17S
IJT - CIR - February 2024 - 18S
IJT - CIR - February 2024 - 19S
IJT - CIR - February 2024 - 20S
IJT - CIR - February 2024 - 21S
IJT - CIR - February 2024 - 22S
IJT - CIR - February 2024 - 23S
IJT - CIR - February 2024 - 24S
IJT - CIR - February 2024 - 25S
IJT - CIR - February 2024 - 26S
IJT - CIR - February 2024 - 27S
IJT - CIR - February 2024 - 28S
IJT - CIR - February 2024 - 29S
IJT - CIR - February 2024 - 30S
IJT - CIR - February 2024 - 31S
IJT - CIR - February 2024 - 32S
IJT - CIR - February 2024 - 33S
IJT - CIR - February 2024 - 34S
IJT - CIR - February 2024 - 35S
IJT - CIR - February 2024 - 36S
IJT - CIR - February 2024 - 37S
IJT - CIR - February 2024 - 38S
IJT - CIR - February 2024 - 39S
IJT - CIR - February 2024 - 40S
IJT - CIR - February 2024 - 41S
IJT - CIR - February 2024 - 42S
IJT - CIR - February 2024 - 43S
IJT - CIR - February 2024 - 44S
IJT - CIR - February 2024 - 45S
IJT - CIR - February 2024 - 46S
IJT - CIR - February 2024 - 47S
IJT - CIR - February 2024 - 48S
IJT - CIR - February 2024 - 49S
IJT - CIR - February 2024 - 50S
IJT - CIR - February 2024 - 51S
IJT - CIR - February 2024 - 52S
IJT - CIR - February 2024 - 53S
IJT - CIR - February 2024 - 54S
IJT - CIR - February 2024 - 55S
IJT - CIR - February 2024 - 56S
IJT - CIR - February 2024 - 57S
IJT - CIR - February 2024 - 58S
IJT - CIR - February 2024 - 59S
IJT - CIR - February 2024 - 60S
IJT - CIR - February 2024 - 61S
IJT - CIR - February 2024 - 62S
IJT - CIR - February 2024 - 63S
IJT - CIR - February 2024 - 64S
IJT - CIR - February 2024 - 65S
IJT - CIR - February 2024 - 66S
IJT - CIR - February 2024 - 67S
IJT - CIR - February 2024 - 68S
IJT - CIR - February 2024 - 69S
IJT - CIR - February 2024 - 70S
IJT - CIR - February 2024 - 71S
IJT - CIR - February 2024 - 72S
IJT - CIR - February 2024 - 73S
IJT - CIR - February 2024 - 74S
IJT - CIR - February 2024 - 75S
IJT - CIR - February 2024 - 76S
IJT - CIR - February 2024 - 77S
IJT - CIR - February 2024 - 78S
IJT - CIR - February 2024 - 79S
IJT - CIR - February 2024 - 80S
IJT - CIR - February 2024 - 81S
IJT - CIR - February 2024 - 82S
IJT - CIR - February 2024 - 83S
IJT - CIR - February 2024 - 84S
IJT - CIR - February 2024 - 85S
IJT - CIR - February 2024 - 86S
IJT - CIR - February 2024 - 87S
IJT - CIR - February 2024 - 88S
IJT - CIR - February 2024 - 89S
IJT - CIR - February 2024 - 90S
IJT - CIR - February 2024 - 91S
IJT - CIR - February 2024 - 92S
IJT - CIR - February 2024 - 93S
IJT - CIR - February 2024 - 94S
IJT - CIR - February 2024 - 95S
IJT - CIR - February 2024 - 96S
IJT - CIR - February 2024 - 97S
IJT - CIR - February 2024 - 98S
IJT - CIR - February 2024 - 99S
IJT - CIR - February 2024 - 100S
IJT - CIR - February 2024 - 101S
IJT - CIR - February 2024 - 102S
IJT - CIR - February 2024 - 103S
IJT - CIR - February 2024 - 104S
IJT - CIR - February 2024 - 105S
IJT - CIR - February 2024 - 106S
IJT - CIR - February 2024 - 107S
IJT - CIR - February 2024 - 108S
IJT - CIR - February 2024 - 109S
IJT - CIR - February 2024 - 110S
IJT - CIR - February 2024 - 111S
IJT - CIR - February 2024 - 112S
IJT - CIR - February 2024 - 113S
IJT - CIR - February 2024 - 114S
IJT - CIR - February 2024 - 115S
IJT - CIR - February 2024 - 116S
IJT - CIR - February 2024 - 117S
IJT - CIR - February 2024 - 118S
IJT - CIR - February 2024 - Cover3
IJT - CIR - February 2024 - Cover4
https://www.nxtbookmedia.com